ABBVIE INC (1ABBV.MI) Stock Fundamental Analysis
Europe - BIT:1ABBV - US00287Y1091 - Common Stock
177.8 EUR
+17.8 (+11.13%)
Taking everything into account, 1ABBV scores 5 out of 10 in our fundamental rating. 1ABBV was compared to 73 industry peers in the Biotechnology industry. While 1ABBV is still in line with the averages on profitability rating, there are concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on 1ABBV.
1. Profitability
1.1 Basic Checks
1ABBV had positive earnings in the past year.
In the past year 1ABBV had a positive cash flow from operations.
Each year in the past 5 years 1ABBV has been profitable.
In the past 5 years 1ABBV always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of 1ABBV (2.71%) is better than 78.38% of its industry peers.
1ABBV has a better Return On Invested Capital (13.81%) than 89.19% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1ABBV is in line with the industry average of 12.51%.
The 3 year average ROIC (13.67%) for 1ABBV is below the current ROIC(13.81%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROIC | 13.81% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
Looking at the Profit Margin, with a value of 6.38%, 1ABBV belongs to the top of the industry, outperforming 81.08% of the companies in the same industry.
In the last couple of years the Profit Margin of 1ABBV has declined.
1ABBV has a Operating Margin of 31.27%. This is amongst the best in the industry. 1ABBV outperforms 89.19% of its industry peers.
1ABBV's Operating Margin has declined in the last couple of years.
The Gross Margin of 1ABBV (70.93%) is better than 66.22% of its industry peers.
1ABBV's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1ABBV is creating some value.
The number of shares outstanding for 1ABBV remains at a similar level compared to 1 year ago.
1ABBV has more shares outstanding than it did 5 years ago.
1ABBV has a worse debt/assets ratio than last year.
2.2 Solvency
1ABBV has an Altman-Z score of 2.26. This is not the best score and indicates that 1ABBV is in the grey zone with still only limited risk for bankruptcy at the moment.
1ABBV has a better Altman-Z score (2.26) than 67.57% of its industry peers.
The Debt to FCF ratio of 1ABBV is 3.86, which is a good value as it means it would take 1ABBV, 3.86 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 1ABBV (3.86) is better than 83.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Altman-Z | 2.26 |
ROIC/WACC1.47
WACC9.42%
2.3 Liquidity
1ABBV has a Current Ratio of 0.74. This is a bad value and indicates that 1ABBV is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of 1ABBV (0.74) is worse than 78.38% of its industry peers.
1ABBV has a Quick Ratio of 0.74. This is a bad value and indicates that 1ABBV is not financially healthy enough and could expect problems in meeting its short term obligations.
1ABBV has a Quick ratio of 0.61. This is in the lower half of the industry: 1ABBV underperforms 79.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
The earnings per share for 1ABBV have decreased by -1.03% in the last year.
1ABBV shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.51% yearly.
The Revenue has been growing slightly by 6.05% in the past year.
The Revenue has been growing by 11.11% on average over the past years. This is quite good.
EPS 1Y (TTM)-1.03%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%12.08%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%6.65%
3.2 Future
The Earnings Per Share is expected to grow by 13.02% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.00% on average over the next years.
EPS Next Y21.26%
EPS Next 2Y19.74%
EPS Next 3Y16.65%
EPS Next 5Y13.02%
Revenue Next Year8.23%
Revenue Next 2Y8.57%
Revenue Next 3Y8.14%
Revenue Next 5Y7%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
1ABBV is valuated rather expensively with a Price/Earnings ratio of 19.65.
Based on the Price/Earnings ratio, 1ABBV is valued cheaply inside the industry as 86.49% of the companies are valued more expensively.
1ABBV is valuated rather cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 14.33, which indicates a correct valuation of 1ABBV.
Based on the Price/Forward Earnings ratio, 1ABBV is valued cheaply inside the industry as 85.14% of the companies are valued more expensively.
1ABBV's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.65 | ||
| Fwd PE | 14.33 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1ABBV indicates a rather cheap valuation: 1ABBV is cheaper than 82.43% of the companies listed in the same industry.
1ABBV's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1ABBV is cheaper than 83.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.14 | ||
| EV/EBITDA | 16.06 |
4.3 Compensation for Growth
1ABBV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of 1ABBV may justify a higher PE ratio.
1ABBV's earnings are expected to grow with 16.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.92
PEG (5Y)7.83
EPS Next 2Y19.74%
EPS Next 3Y16.65%
5. Dividend
5.1 Amount
1ABBV has a Yearly Dividend Yield of 3.08%.
Compared to an average industry Dividend Yield of 17.14, 1ABBV pays a better dividend. On top of this 1ABBV pays more dividend than 94.59% of the companies listed in the same industry.
1ABBV's Dividend Yield is a higher than the S&P500 average which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.08% |
5.2 History
The dividend of 1ABBV is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
304.54% of the earnings are spent on dividend by 1ABBV. This is not a sustainable payout ratio.
1ABBV's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP304.54%
EPS Next 2Y19.74%
EPS Next 3Y16.65%
BIT:1ABBV (8/26/2025, 7:00:00 PM)
177.8
+17.8 (+11.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.78%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap314.09B
Analysts78.92
Price Target188.54 (6.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.08% |
Yearly Dividend5.34
Dividend Growth(5Y)7.72%
DP304.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.04%
Min EPS beat(2)0.95%
Max EPS beat(2)1.14%
EPS beat(4)4
Avg EPS beat(4)0.75%
Min EPS beat(4)0.02%
Max EPS beat(4)1.14%
EPS beat(8)7
Avg EPS beat(8)0.76%
EPS beat(12)9
Avg EPS beat(12)0.46%
EPS beat(16)11
Avg EPS beat(16)0.4%
Revenue beat(2)2
Avg Revenue beat(2)0.93%
Min Revenue beat(2)0.63%
Max Revenue beat(2)1.23%
Revenue beat(4)2
Avg Revenue beat(4)0.24%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)5
Avg Revenue beat(12)-0.32%
Revenue beat(16)5
Avg Revenue beat(16)-0.81%
PT rev (1m)-0.16%
PT rev (3m)-1.93%
EPS NQ rev (1m)0.81%
EPS NQ rev (3m)1.22%
EPS NY rev (1m)-0.93%
EPS NY rev (3m)-1.5%
Revenue NQ rev (1m)0.93%
Revenue NQ rev (3m)1.31%
Revenue NY rev (1m)1.05%
Revenue NY rev (3m)1.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.65 | ||
| Fwd PE | 14.33 | ||
| P/S | 6.3 | ||
| P/FCF | 20.14 | ||
| P/OCF | 19.05 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.06 |
EPS(TTM)9.05
EY5.09%
EPS(NY)12.4
Fwd EY6.98%
FCF(TTM)8.83
FCFY4.96%
OCF(TTM)9.33
OCFY5.25%
SpS28.23
BVpS-0.09
TBVpS-44.94
PEG (NY)0.92
PEG (5Y)7.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROCE | 18.72% | ||
| ROIC | 13.81% | ||
| ROICexc | 14.74% | ||
| ROICexgc | 370.81% | ||
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% | ||
| FCFM | 31.27% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Debt/EBITDA | 2.58 | ||
| Cap/Depr | 12.62% | ||
| Cap/Sales | 1.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 72.74% | ||
| Profit Quality | 489.9% | ||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z | 2.26 |
F-Score6
WACC9.42%
ROIC/WACC1.47
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.03%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%12.08%
EPS Next Y21.26%
EPS Next 2Y19.74%
EPS Next 3Y16.65%
EPS Next 5Y13.02%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%6.65%
Revenue Next Year8.23%
Revenue Next 2Y8.57%
Revenue Next 3Y8.14%
Revenue Next 5Y7%
EBIT growth 1Y13.81%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year19.96%
EBIT Next 3Y14.99%
EBIT Next 5Y11.27%
FCF growth 1Y-26.45%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-24.5%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%